Long Term Investment, Biotech & High Yield Dividend Stocks

[califax]

playing HGSI

pre-market (now) $1.65





http://shortsqueeze.com/?symbol=hgsi&submit=Short+Quote%99

Human Genome Sciences Inc. $ 1.30
HGSI
Short Interest (Shares Short) 9,178,900
Days To Cover (Short Interest Ratio) 4.1
Short Percent of Float 7.02 %
Short Interest - Prior 9,595,600
Short % Increase / Decrease -4.34 %
Short Squeeze Ranking™ -24
% From 52-Wk High ($ 8.00 ) -515.38 %
% From 52-Wk Low ($ 0.45 ) 65.38 %
% From 200-Day MA ($ 2.22 ) -70.77 %
% From 50-Day MA ($ 1.11 ) 14.62 %
Price % Change (52-Week) -82.50 %
Shares Float 130,690,000
Total Shares Outstanding 135,745,696
% Owned by Insiders 8.41 %
% Owned by Institutions 77.20 %
Market Cap. $ 176,469,405
Trading Volume - Today 2,410,815
Trading Volume - Average 2,243,400
Trading Volume - Today vs. Average 107.46 %
Earnings Per Share -1.81
PE Ratio
Record Date 2009-AprilB
Sector Healthcare
Industry Biotechnology
Exchange NAS

http://ih.advfn.com/p.php?pid=nmona&cb=1240832302&article=37435117&symbol=N^HGSI

Date : 04/25/2009 @ 10:00AM
Source : PR Newswire

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) -

ROCKVILLE, Md., April 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (NASDAQ:HGSI) today reported that the final results of two pivotal Phase 3 trials demonstrate that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in the treatment of patients with chronic hepatitis C. The Phase 3 results were the subject of two late-breaker oral presentations today in Copenhagen at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"The Phase 3 data presented at EASL show that Albuferon, with half the injections, achieved a rate of sustained virologic response comparable to Pegasys," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "Importantly, the rates of serious and/or severe adverse events were also comparable in these studies. We plan to file global marketing applications in fall 2009, following discussions with regulatory authorities - and we believe that Albuferon, assuming licensure, could become a leading treatment for chronic hepatitis C."

The Phase 3 studies, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin, for use in the treatment of interferon-naive patients with chronic hepatitis C. ACHIEVE 1 was conducted in patients infected with genotype 1 virus, and ACHIEVE 2/3 was conducted in patients with genotypes 2 and 3 virus. The two studies treated a combined total of 2255 treatment-naive patients.

"The results of two Phase 3 trials demonstrate that 900-mcg albinterferon alfa-2b administered every two weeks provides efficacy comparable to peginterferon alfa-2a administered weekly, with a positive safety profile," said David Nelson, M.D., Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section, University of Florida. Dr. Nelson presented the results from ACHIEVE 2/3.

Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany, presented the ACHIEVE 1 results, and said, "The data presented at EASL suggest that albinterferon alfa-2b has the potential to become an important and novel treatment option for patients with chronic hepatitis C."

...

http://finance.yahoo.com/news/Human-Genome-Sciences-to-prnews-15002108.html?.v=1

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2009. These results are expected to be disclosed on Wednesday, April 29, 2009, after the capital markets close.